Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients

Department of Sport and Exercise Physiology, University of Vienna, Vienna, Austria.
British Journal of Sports Medicine (Impact Factor: 5.03). 10/2006; 40(9):773-8. DOI: 10.1136/bjsm.2006.027250
Source: PubMed


Previous studies have demonstrated that in patients with coronary artery disease (CAD) upward deflection of the heart rate (HR) performance curve can be observed and that this upward deflection and the degree of the deflection are correlated with a diminished stress dependent left ventricular function. Magnesium supplementation improves endothelial function, exercise tolerance, and exercise induced chest pain in patients with CAD. Purpose: We studied the effects of oral magnesium therapy on exercise dependent HR as related to exercise tolerance and resting myocardial function in patients with CAD.
In a double blind controlled trial, 53 male patients with stable CAD were randomised to either oral magnesium 15 mmol twice daily (n = 28, age 61+/-9 years, height 171+/-7 cm, body weight 79+/-10 kg, previous myocardial infarction, n = 7) or placebo (n = 25, age 58+/-10 years, height 172+/-6 cm, body weight 79+/-10 kg, previous myocardial infarction, n = 6) for 6 months. Maximal oxygen uptake (VO2max), the degree and direction of the deflection of the HR performance curve described as factor k<0 (upward deflection), and the left ventricular ejection fraction (LVEF) were the outcomes measured.
Magnesium therapy for 6 months significantly increased intracellular magnesium levels (32.7+/-2.5 v 35.6+/-2.1 mEq/l, p<0.001) compared to placebo (33.1+/-3.1.9 v 33.8+/-2.0 mEq/l, NS), VO2max (28.3+/-6.2 v 30.6+/-7.1 ml/kg/min, p<0.001; 29.3+/-5.4 v 29.6+/-5.2 ml/kg/min, NS), factor k (-0.298+/-0.242 v -0.208+/-0.260, p<0.05; -0.269+/-0.336 v -0.272+/-0.335, NS), and LVEF (58+/-11 v 67+/-10%, p<0.001; 55+/-11 v 54+/-12%, NS).
The present study supports the intake of oral magnesium and its favourable effects on exercise tolerance and left ventricular function during rest and exercise in stable CAD patients.

Download full-text


Available from: Manfred Wonisch
  • Source
    • "They concluded that the Mg compound could improve the skin microvasculature of diabetic rats by potentiating the nitric oxide pathway [12]. Benefit of Mg repletion in patients suffering from cardiovascular diseases is evident [13], and some Mg-containing agents have been recommended for Mg repletion in patients with cardiovascular diseases: Magnosolv-Granulat (Mg carbonate and Mg oxide), magnerot (Mg orotate), Asparkam-L (K,Mg l-aspartate) and Panangin (K,Mg aspartate). However, the bioavailability of some of these compounds has been shown to be lower than that of Mg chloride and some organic Mg compounds, such as Mg l-aspartate, Mg oxybutirate and Mg N-acetyltaurate [14] [15]. "

    Full-text · Article · Jan 2014 · Journal of Trace Elements in Medicine and Biology
  • Source
    • "Hence, nutritional insurance supplementation may provide the unexpected benefit of alleviating adverse health effects of excess phosphate. Moreover, ensuring good magnesium status may be beneficial for cardiovascular health while reducing risk for diabetes and colorectal cancer, and supplemental calcium may modestly aid maintenance of bone density [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107]. Nonetheless, in the context of CKD, calcium salts, as opposed to non-calcium phosphate binders, have been associated with more coronary artery calcification, a greater risk for hypercalcemia , and a greater calcium-phosphate product; as one would suspect, PTH is better suppressed by supplemental calcium [108–110]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased fasting serum phosphate within the normal physiological range has been linked to increased cardiovascular risk in prospective epidemiology; increased production of fibroblast growth factor 23 (FGF23), and direct vascular effects of phosphate, may mediate this risk. Although dietary phosphate intake does not clearly influence fasting serum phosphate in those with normal renal function, increased phosphate intake can provoke an increase in FGF23, and in diurnal phosphate levels, and hence may adversely influence vascular health. Dietary phosphate absorption can be moderated by emphasizing plant-based dietary choices (which provide phosphate in less-bioavailable forms), avoidance of processed foods containing inorganic phosphate food additives, and by ingestion of phosphate-binder drugs, magnesium supplements, or niacin, which precipitate phosphate or suppress its gastrointestinal absorption. The propensity of dietary phosphate to promote vascular calcification may be opposed by optimal intakes of magnesium, vitamin K, and vitamin D; the latter should also counter the tendency of phosphate to elevate parathyroid hormone.
    Full-text · Article · Jan 2013 · Nutrition
  • [Show abstract] [Hide abstract]
    ABSTRACT: Practice Guidelines for Exercise Testing. Exercise testing is a standard procedure in cardiology. This has not changed with newer diag-
    No preview · Article · Jan 2014 · Atemwegs- und Lungenkrankheiten
Show more